<DOC>
	<DOC>NCT00401570</DOC>
	<brief_summary>This clinical trial is being conducted to determine tumor response and preliminary safety of a monoclonal antibody that specifically binds to a cell surface receptor (α5β1 integrin) that is required for the establishment of new blood vessels during tumor growth, a process known as angiogenesis.</brief_summary>
	<brief_title>A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Male or female, 18 years of age or older. Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas. May have received prior immunotherapy (including monoclonal antibodies) or vaccine therapies. Measurable disease, according to RECIST criteria. Negative pregnancy test (women of childbearing potential only). Pretreatment laboratory levels that meet specific criteria. Prior treatment with Volociximab (M200) or inhibitors of α5β1 integrin (antibodies or small molecules) or gemcitabine and other chemotherapeutic regimens. Known hypersensitivity to murine proteins or chimeric antibodies or other components of the product. Use of any investigational drug within 4 weeks prior to screening or 5 halflives of the prior investigational drug (whichever is longer). Monoclonal antibody therapy within 4 weeks of the first dose of Volociximab. Central Nervous System (CNS) tumor or metastasis. History of bleeding disorders within the past year. Medical conditions that may be exacerbated by bleeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Antibody</keyword>
	<keyword>Pancreas</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Cancer</keyword>
	<keyword>Pancreatic</keyword>
</DOC>